Bristol BuSpar Metabolite Data Requested By FDA Before Final Patent Listing
Executive Summary
FDA is requesting additional information from Bristol-Myers Squibb on the company's BuSpar (buspirone) metabolite patent before permanently listing it in the "Orange Book."
You may also be interested in...
Product-By-Process Patents In Orange Book Should Claim Novel Products – FTC
FDA should ensure that product-by-process patents listed in the "Orange Book" claim only novel products, the Federal Trade Commission said in comments on FDA's proposed rule
Product-By-Process Patents In Orange Book Should Claim Novel Products – FTC
FDA should ensure that product-by-process patents listed in the "Orange Book" claim only novel products, the Federal Trade Commission said in comments on FDA's proposed rule
BuSpar Appeal: Bristol Argues Mylan Evaded Waxman/Hatch By Filing Suit
Mylan attempted to circumvent Waxman/Hatch procedures by filing suit against Bristol-Myers Squibb over its BuSpar (buspirone) metabolite patent before issuing a Paragraph IV certification, Bristol argued before the federal circuit appeals court in Washington D.C. July 12.